New hope for tough colorectal cancer: JSKN003 trial launches
NCT ID NCT07384377
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new drug called JSKN003 against standard treatments for people with advanced HER2-positive colorectal cancer that has not responded to three common chemotherapies. About 123 participants will be randomly assigned to receive either JSKN003 or a standard treatment. The goal is to see if JSKN003 can slow cancer growth and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JSKN003 (a drug given by IV every 3 weeks)
What this could lead to
If it works, this could offer a new treatment option for people with advanced HER2-positive colorectal cancer who have run out of standard options.
What could go wrong
This is an early-stage Phase 3 trial with only 123 participants, so results may not apply to everyone. The drug may not work better than existing treatments and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••